DjamgaMind: Audio Intelligence for the C-Suite (Daily AI News, Energy, Healthcare, Finance)
Full-Stack AI Intelligence. Zero Noise.The definitive audio briefing for the C-Suite and AI Architects. From Daily News and Strategic Deep Dives to high-density Industrial & Regulatory Intelligence—decoded at the speed of the AI era. . 👉 Start your specialized audio briefing today at Djamgamind.com
AI Jobs and Career
I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
- Full Stack Engineer [$150K-$220K]
- Software Engineer, Tooling & AI Workflow, Contract [$90/hour]
- DevOps Engineer, India, Contract [$90/hour]
- More AI Jobs Opportunitieshere
| Job Title | Status | Pay |
|---|---|---|
| Full-Stack Engineer | Strong match, Full-time | $150K - $220K / year |
| Developer Experience and Productivity Engineer | Pre-qualified, Full-time | $160K - $300K / year |
| Software Engineer - Tooling & AI Workflows (Contract) | Contract | $90 / hour |
| DevOps Engineer (India) | Full-time | $20K - $50K / year |
| Senior Full-Stack Engineer | Full-time | $2.8K - $4K / week |
| Enterprise IT & Cloud Domain Expert - India | Contract | $20 - $30 / hour |
| Senior Software Engineer | Contract | $100 - $200 / hour |
| Senior Software Engineer | Pre-qualified, Full-time | $150K - $300K / year |
| Senior Full-Stack Engineer: Latin America | Full-time | $1.6K - $2.1K / week |
| Software Engineering Expert | Contract | $50 - $150 / hour |
| Generalist Video Annotators | Contract | $45 / hour |
| Generalist Writing Expert | Contract | $45 / hour |
| Editors, Fact Checkers, & Data Quality Reviewers | Contract | $50 - $60 / hour |
| Multilingual Expert | Contract | $54 / hour |
| Mathematics Expert (PhD) | Contract | $60 - $80 / hour |
| Software Engineer - India | Contract | $20 - $45 / hour |
| Physics Expert (PhD) | Contract | $60 - $80 / hour |
| Finance Expert | Contract | $150 / hour |
| Designers | Contract | $50 - $70 / hour |
| Chemistry Expert (PhD) | Contract | $60 - $80 / hour |
Longevity gene therapy and AI – What is on the horizon?
Gene therapy holds promise for extending human lifespan and enhancing healthspan by targeting genes associated with aging processes. Longevity gene therapy, particularly interventions focusing on genes like TERT (telomerase reverse transcriptase), Klotho, and Myostatin, is at the forefront of experimental research. Companies such as Bioviva, Libella, and Minicircle are pioneering these interventions, albeit with varying degrees of transparency and scientific rigor.
TERT, Klotho, and Myostatin in Longevity
- TERT: The TERT gene encodes for an enzyme essential in telomere maintenance, which is linked to cellular aging. Overexpression of TERT in model organisms has shown potential in lengthening telomeres, potentially delaying aging.
- Klotho: This gene plays a crucial role in regulating aging and lifespan. Klotho protein has been associated with multiple protective effects against age-related diseases.
- Myostatin: Known for its role in regulating muscle growth, inhibiting Myostatin can result in increased muscle mass and strength, which could counteract some age-related physical decline.
The Experimental Nature of Longevity Gene Therapy
The application of gene therapy for longevity remains largely experimental. Most available data come from preclinical studies, primarily in animal models. Human data are scarce, raising questions about efficacy, safety, and potential long-term effects. The ethical implications of these experimental treatments, especially in the absence of robust data, are significant, touching on issues of access, consent, and potential unforeseen consequences.
Companies Offering Longevity Gene Therapy
- Bioviva: Notably involved in this field, Bioviva has been vocal about its endeavors in gene therapy for aging. While they have published some data from mouse studies, human data remain limited.
- Libella and Minicircle: These companies also offer longevity gene therapies but face similar challenges in providing comprehensive human data to back their claims.
Industry Perspective vs. Public Discourse
The discourse around longevity gene therapy is predominantly shaped by those within the industry, such as Liz Parrish of Bioviva and Bryan Johnson. While their insights are valuable, they may also be biased towards promoting their interventions. The lack of widespread discussion on platforms like Reddit and Twitter, especially from independent sources or those outside the industry, points to a need for greater transparency and peer-reviewed research.

Ethical and Regulatory Considerations
The ethical and regulatory landscape for gene therapy is complex, particularly for treatments aimed at non-disease conditions like aging. The experimental status of longevity gene therapies raises significant ethical questions, particularly around informed consent and the potential long-term impacts. Regulatory bodies are tasked with balancing the potential benefits of such innovative treatments against the risks and ethical concerns, requiring a robust framework for clinical trials and approval processes.
Longevity Gene Therapy and AI
Integrating Artificial Intelligence (AI) into longevity gene therapy represents a groundbreaking intersection of biotechnology and computational sciences. AI and machine learning algorithms are increasingly employed to decipher complex biological data, predict the impacts of genetic modifications, and optimize therapy designs. In the context of longevity gene therapy, AI can analyze vast datasets from genomics, proteomics, and metabolomics to identify new therapeutic targets, understand the intricate mechanisms of aging, and predict individual responses to gene therapies. This computational power enables researchers to simulate the effects of gene editing or modulation before actual clinical application, enhancing the precision and safety of therapies. Furthermore, AI-driven platforms facilitate the personalized tailoring of gene therapy interventions, taking into account the unique genetic makeup of each individual, which is crucial for effective and minimally invasive treatment strategies. The synergy between AI and longevity gene therapy accelerates the pace of discovery and development in this field, promising more rapid translation of research findings into clinical applications that could extend human healthspan and lifespan.
AI-Powered Professional Certification Quiz Platform
Web|iOs|Android|Windows
Are you passionate about AI and looking for your next career challenge? In the fast-evolving world of artificial intelligence, connecting with the right opportunities can make all the difference. We're excited to recommend Mercor, a premier platform dedicated to bridging the gap between exceptional AI professionals and innovative companies.
Whether you're seeking roles in machine learning, data science, or other cutting-edge AI fields, Mercor offers a streamlined path to your ideal position. Explore the possibilities and accelerate your AI career by visiting Mercor through our exclusive referral link:
Find Your AI Dream Job on Mercor
Your next big opportunity in AI could be just a click away!
Moving Forward
For longevity gene therapy to advance from experimental to accepted medical practice, several key developments are needed:
- Robust Human Clinical Trials: Rigorous, peer-reviewed clinical trials involving human participants are essential to establish the safety and efficacy of gene therapies for longevity.
- Transparency and Peer Review: Open sharing of data and peer-reviewed publication of results can help build credibility and foster a more informed public discourse.
- Ethical and Regulatory Frameworks: Developing clear ethical guidelines and regulatory pathways for these therapies will be crucial in ensuring they are deployed responsibly.
The future of longevity gene therapy is fraught with challenges but also holds immense promise. As the field evolves, a multidisciplinary approach involving scientists, ethicists, regulators, and the public will be crucial in realizing its potential in a responsible and beneficial manner.
AI- Powered Jobs Interview Warmup For Job Seekers

⚽️Comparative Analysis: Top Calgary Amateur Soccer Clubs – Outdoor 2025 Season (Kids' Programs by Age Group)
Longevity gene therapy and AI: Annex
What are the top 10 most promising potential longevity therapies being researched?
I think the idea of treating aging as a disease that’s treatable and preventable in some ways is a really necessary focus. The OP works with some of the world’s top researchers using HBOT as part of that process to increase oxygen in the blood and open new pathways in the brain to address cognitive decline and increase HealthSpan (vs. just lifespan). Pretty cool stuff!
HBOT in longevity research stands for “hyperbaric oxygen therapy.” It has been the subject of research for its potential effects on healthy aging. Several studies have shown that HBOT can target aging hallmarks, including telomere shortening and senescent cell accumulation, at the cellular level. For example, a prospective trial found that HBOT can significantly modulate the pathophysiology of skin aging in a healthy aging population, indicating effects such as angiogenesis and senescent cell clearance. Additionally, research has demonstrated that HBOT may induce significant senolytic effects, including increasing telomere length and decreasing senescent cell accumulation in aging adults. The potential of HBOT in healthy aging and its implications for longevity are still being explored, and further research is needed to fully understand its effects and potential applications.
AI Jobs and Career
And before we wrap up today's AI news, I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
2- Are they also looking into HBOT as a treatment for erectile dysfunction?
Definitely! Dr. Shai Efrati has been doing research around that and had a study published in the Journal of Sexual Medicine. Dr. Efrati and his team found that 80% of men “reported improved erections” after HBOT therapy: https://www.nature.com/articles/s41443-018-0023-9
3- I think cellular reprogramming seems to be one of the most promising approaches https://www.lifespan.io/topic/yamanaka-factors/
Invest in your future today by enrolling in this Azure Fundamentals - Pass the Azure Fundamentals Exam with Ease: Master the AZ-900 Certification with the Comprehensive Exam Preparation Guide!
- AWS Certified AI Practitioner (AIF-C01): Conquer the AWS Certified AI Practitioner exam with our AI and Machine Learning For Dummies test prep. Master fundamental AI concepts, AWS AI services, and ethical considerations.
- Azure AI Fundamentals: Ace the Azure AI Fundamentals exam with our comprehensive test prep. Learn the basics of AI, Azure AI services, and their applications.
- Google Cloud Professional Machine Learning Engineer: Nail the Google Professional Machine Learning Engineer exam with our expert-designed test prep. Deepen your understanding of ML algorithms, models, and deployment strategies.
- AWS Certified Machine Learning Specialty: Dominate the AWS Certified Machine Learning Specialty exam with our targeted test prep. Master advanced ML techniques, AWS ML services, and practical applications.
- AWS Certified Data Engineer Associate (DEA-C01): Set yourself up for promotion, get a better job or Increase your salary by Acing the AWS DEA-C01 Certification.
4-Next-gen senolytics (eg, Rubedo, Oisin, Deciduous).
Cellular rejuvenation aka partial reprogramming (as someone else already said) but not just by Yamanaka (OSKM) factors or cocktail variants but also by other novel Yamanaka-factor alternatives.
Stem cell secretions.
Treatments for aging extra-cellular matrix (ECM).
5- Rapamycin is the most promising short term.
I see a lot of people saying reprogramming, and I think the idea is promising but as someone who worked on reprogramming cells in vitro I can tell you that any proof of concepts in vivo large animal models is far aways.
6- Blood focused therapies ( dilution, plasma refactoring, e5, exosomes) perhaps look at yuvan research.
7- I think plasmapheresis is a technology most likely to be proven beneficial in the near term and also a technology that can be scaled and offered for reasonable prices.
8- Bioelectricity, if we succeed in interpreting the code of electrical signals By which cells communicate , we can control any tissue growth and development including organs regeneration
9- Gene therapy and reprogramming will blow the lid off the maximum lifespan. Turning longevity genes on/expressing proteins that repair cellular damage and reversing epigenetic changes that occur with aging.
10- I don’t think anything currently being researched (that we know of) has the potential to take us to immortality. That’ll likely end up requiring some pretty sophisticated nanotechnology. However, the important part isn’t getting to immortality, but getting to LEV. In that respect, I’d say senolytics and stem cell treatments are both looking pretty promising. (And can likely achieve more in combination than on their own.)
11- Spiroligomers to remove glucosepane from the ECM.
12- Yuvan Research. Look up the recent paper they have with Steve Horvath on porcine plasma fractions.
13- This OP thinks most of the therapies being researched will end up having insignificant effects. The only thing that looks promising to me is new tissue grown from injected stem cells or outright organ replacement. Nothing else will address DNA damage, which results in gene loss, disregulation of gene expression, and loss of suppression of transposable elements.
14- A couple that haven’t been mentioned:
Cancer:
The killer T-cells that target MR-1 and seem to be able to find and kill all common cancer types.
Also Maia Biotech’s THIO (“WILT 2.0”)
Mitochondria: Mitochondrial infusion that lasts or the allotopic expression of the remaining proteins SENS is working on.
15- Look for first updates coming from altos labs.
Altos Labs is a biotechnology research company focused on unraveling the deep biology of cell rejuvenation to reverse disease and develop life extension therapies that can halt or reverse the human aging process. The company’s goal is to increase the “healthspan” of humans, with longevity extension being an “accidental consequence” of their work. Altos Labs is dedicated to restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and disabilities that can occur throughout life. The company is working on specialized cell therapies based on induced pluripotent stem cells to achieve these objectives. Altos Labs is known for its atypical focus on basic research without immediate prospects of a commercially viable product, and it has attracted significant investment, including a $3 billion funding round in January 2022. The company’s research is based on the fundamental biology of cell rejuvenation, aiming to understand and harness the ability of cells to resist stressors that give rise to disease, particularly in the context of aging.
16– not so much a “therapy” but I think research into growing human organs may be very promising long term. Being able to get organ transplants made from your own cells means zero rejection issues and no limitations of supply for transplants. Near term drugs like rampamycin show good potential for slowing the aging process and are in human trials.
What is biological reprogramming technology?
Biological reprogramming technology involves the process of converting specialized cells into a pluripotent state, which can then be directed to become a different cell type. This technology has significant implications for regenerative medicine, disease modeling, and drug discovery. It is based on the concept that a cell’s identity is defined by the gene regulatory networks that are active in the cell, and these networks can be controlled by transcription factors. Reprogramming can be achieved through various methods, including the introduction of exogenous factors such as transcription factors. The process of reprogramming involves the erasure and remodeling of epigenetic marks, such as DNA methylation, to reset the cell’s epigenetic memory, allowing it to be directed to different cell fates. This technology has the potential to create new cells for regenerative medicine and to provide insights into the fundamental basis of cell identity and disease.
See also
- Gene Therapy Basics for foundational understanding of gene therapy techniques and applications.
- [Aging and Longevity Research]
- Bryan Johnson, a 45-year-old biotech founder, hopes to rewind the clock of his body a few decades through a program he started, called Project Blueprint.
Links to external Longevity-related sites
Outline of Life Extension on Wikipedia
Index of life extension related Wikipedia articles
Accelerate cure for Alzheimers
Aging in Motion
Aging Matters
Aging Portfolio
Alliance for Aging Research
Alliance for Regenerative Medicine
American Academy of Anti-Aging Medicine
American Aging Association
American Federation for Aging Research
American Society on Aging
Blue Zones – /r/BlueZones
Brain Preservation Foundation
British Society for Research on Aging
Calico Labs
Caloric Restriction Society
Church of Perpetual Life
Coalition for Radical Life Extension
Cohbar
Dog Aging Project
ELPI Foundation for Indefinite Lifespan
Fight Aging! Blog
Found My Fitness
Friends of NIA
Gerontology Wiki
Geroscience.com
Global Healthspan Policy Institute
Health Extension
Healthspan Campaign
HEALES
Humanity+ magazine
Humanity+ wiki
International Cell Senescence Association
International Longevity Alliance
International Longevity Centre Global Alliance
International Society on Aging and Disease
Juvena Therapeutics
Leucadia Therapeutics
LEVF
Life Extension Advocacy Foundation
Life Extension Foundation
Lifeboat Foundation
Lifespan.io
Longevity History
Longevity Vision Fund
LongLongLife
Loyal for Dogs Lysoclear
MDI Biological Laboratory
Methuselah Foundation
Metrobiotech
New Organ Alliance
Nuchido
Oisin Biotechnologies
Organ Preservation Alliance
Palo Alto Longevity Prize
Rejuvenaction Blog
Rubedo Life Sciences
Samumed
Senolytx
SENS
Stealth BioTherapeutics
The War On Aging
Unity Biotechnologies
Water Bear Lair
Good Informational Sites:
Programmed Aging Info
Senescence Info
Experimental Gerontology Journal
Mechanisms of Ageing and Development Journal
Schools and Academic Institutions:
Where to do a PhD on aging – a list of labs
Alabama Research Institute on Aging
UT Barshop Institute
Biogerontology Research Foundation
Buck Institute
Columbia Aging Center
Gerontology Research Group
Huffington Center on Aging
Institute for Aging Research – Harvard
Iowa State University Gerontology
Josh Mitteldorf
Longevity Consortium
Max Planck Institute for Biology of Aging – Germany
MIT Agelab
National Institute on Aging
Paul F. Glenn Center for Aging Research – University of Michigan
PennState Center for Healthy Aging
Princeton Longevity Center
Regenerative Sciences Institute
Kogod Center on Aging – Mayo clinic
Salk Institute
Stanford Center on Longevity
Stanford Brunet Lab
Supercenterian Research Foundation
Texas A&M Center for translational research on aging
Gerontological Society of America
Tufts Human Nutrition and Aging Research
UAMS Donald Reynolds Center on Aging
UCLA Longevity Center
UCSF Memory and Aging Center
UIC Center for research on health and aging
University of Iowa Center on Aging
University of Maryland Center for research on aging
University of Washington Biology of Aging
USC School of Gerontology
Wake Forest Institute of Regenerative Medicine
Yale Center for Research on Aging
- I think most companies are building AI backwardsby /u/raktimsingh22 (Artificial Intelligence (AI)) on May 17, 2026 at 2:46 pm
Everyone keeps talking about smarter AI. Bigger models. Longer context windows. More autonomous agents. Better reasoning. Better coding. Better memory. But I think we’re missing the real problem. An AI system can sound intelligent… and still operate on completely broken reality. Imagine an AI agent: approving refunds escalating incidents updating records contacting customers changing prices triggering workflows Now ask a simple question: How does the AI know the reality it sees is actually correct? Not “technically accessible.” Actually correct. Because enterprise reality is messy: stale systems conflicting databases outdated approvals missing context silent exceptions contradictory records unclear ownership shifting policies And then there’s an even bigger question: Even if the AI knows something… is it actually allowed to act on it? Under whose authority? With what limits? Who is accountable? Can the action be reversed? What happens if the AI is wrong? That’s why I’m starting to think the future AI stack is not just: data → model → agent → action There are missing runtime layers in between. The mental model I’ve been exploring is: SENSE → reality representation CORE → reasoning DRIVER → governed action And honestly, it feels like the industry is massively overinvested in CORE. We obsess over intelligence. But the real bottlenecks may become: representation quality legitimacy authority boundaries reversibility accountability runtime governance In other words: The biggest AI failures may not come from “bad intelligence.” They may come from machines acting on incomplete reality with unclear authority. And I think this becomes a huge issue once AI moves from: “helping humans” to “acting inside institutions.” Curious what others here are seeing. Are companies actually solving these layers internally? Or are most organizations still mainly focused on model capability and agent demos right now? submitted by /u/raktimsingh22 [link] [comments]
- OpenAI seals deal in Malta to give all Maltese access to ChatGPT Plusby /u/shikizen (Artificial Intelligence) on May 17, 2026 at 2:44 pm
"U.S. artificial intelligence company OpenAI said on Saturday it had signed a deal with the government of Malta to give all residents access to its ChatGPT Plus service for one year after they follow a course on how to use AI." submitted by /u/shikizen [link] [comments]
- What are the concerns regarding the long term use of AI? What are the benefits?by /u/ChipUnfair3345 (Artificial Intelligence) on May 17, 2026 at 2:23 pm
I’m not at all educated about the subject of AI. I am just an average 9-5 US citizen that doom scrolls Instagram and Reddit after work that has used ChatGPT for a variety of reasons. I’ve used AI to help me to prepare myself for job interviews. I have used it to scan essays or important emails for any grammar or errors I might have missed. I’ve also used it for my hobbies; I create cosplays and I use it to plan out and prepare for creating. I’m quite new so having AI let me know the materials that would work best as well as laying out the most efficient steps in order has taken away so much stress. I also do the NYT crosswords; When I complete the puzzle and find my numerous mistakes I ask AI for the best options and their definitions. It helps me understand and learn crossword “language” better. To sum it up, I’m an average, boring mid 20s human and want to understand more about the complexities of the AI dilemma and the benefits it has. Not just what my feed or news wants to focus on but the dilemma as a whole. submitted by /u/ChipUnfair3345 [link] [comments]
- AsymFlow Claims More Realistic AI Images by Moving Beyond Latent Diffusionby /u/techzexplore (Artificial Intelligence) on May 17, 2026 at 1:00 pm
Researchers at Stanford just published a way around this. AsymFlow doesn’t ask you to abandon your latent model or train a pixel model from scratch. It takes what you already have and converts it. And the result beats the latent model it started from. submitted by /u/techzexplore [link] [comments]
- We are in the gaslighting phase of AI adoptionby /u/RevolutionStill4284 (Artificial Intelligence) on May 17, 2026 at 11:43 am
The real hallucination going on in the industry right now is not that AI sometimes makes things up, because that's well known. What's really concerning is that companies are acting like these systems are way more mature, reliable, and production-ready than they actually are. In my opinion, there’s a reason this keeps going on, and that reason is that, for a lot of organizations, the downside of being wrong is basically very low. If the AI rollout works out, the leadership gets to brag about innovation, the headlines, the stock bump, the forward-thinking image. If it blows up, they can just dump the fallout onto workers. Suddenly the employee: - wasn’t adapting fast enough - didn’t know how to use the tools - fell behind But the no 1 🏆 most spectacular sentence is: "wasn’t AI-native enough" 🤡 Basically the company gets to push experimental systems into production, spin the wheel, and still come out mostly fine either way. If things go sideways, there’s always somebody lower down the ladder to pin it on, and that's when the gaslighting part kicks in. Workers are being told to downplay what they can clearly see with their own eyes: hallucinations, fragile workflows, agents falling apart, bad outputs wrapped in confident language, hours of cleanup and verification work. Those hours are heavily discounted by a leadership believing AI should already be making us all 100X engineers. If the workers point any of this out too directly, they risk getting painted as outdated, resistant, or somehow incapable, so the vast majority simply stays quiet, pretending the emperor has beautiful clothes. We're all testing somebody else's roadmap, and this is a story about both AI vendors and organizations offloading experimental risk onto individual workers while pretending the technology is already solid enough to bet people’s careers on. submitted by /u/RevolutionStill4284 [link] [comments]
- spotted at graduation todayby /u/Complete-Sea6655 (Artificial Intelligence) on May 17, 2026 at 11:00 am
yeah, it is kinda funny but also kinda sad 🙁 is university even worth it anymore, you don't need a degree to use Claude submitted by /u/Complete-Sea6655 [link] [comments]
- A mini-computer you run from a folder on your computer that can train small LLMSby /u/TheOnlyVibemaster (Artificial Intelligence (AI)) on May 17, 2026 at 10:51 am
Hey everyone, Most people build 8-bit computers to run Pong or Tetris. I wanted to see if I could push a custom 8-bit architecture to do something much harder: train a neural network from scratch. I built VirtualPC, an open-source 8-bit computer system simulated from basic NAND gates up to a functional CPU that can train a small neural net from a folder on your computer. Repository: https://github.com/ninjahawk/VirtualPC › The ML Core Instead of importing PyTorch, everything happens at the bare-metal assembly level: Custom ISA: The Instruction Set Architecture was designed to handle the math needed for machine learning. Low-Level Training: The CPU executes forward and backward passes directly through custom assembly code. Matrix Math on 8-bit: Overcoming severe memory limits using disk-backed memory swapping to store weights. › The Architecture Python-Based VM: Runs the entire simulated hardware environment. Custom Assembler: Translates raw assembly files into machine code binary. Full Stack OS: Handles basic I/O and memory management from the ground up. Building this taught me exactly how machine learning math translates into physical CPU cycles. The project is completely open-source and free to mess around with. submitted by /u/TheOnlyVibemaster [link] [comments]
- jagged intelligence - possibly a destination not a temporary detourby /u/theonejvo (Artificial Intelligence) on May 17, 2026 at 10:34 am
When u/karpathy described the strange shape of modern AI capability, he used a useful word for it. The idea is that the surface of what a model can do is not smooth, the way human ability is roughly smooth, but uneven, with sharp peaks of near-superhuman performance rising directly next to valleys of embarrassing failure. The classic demonstration is to ask a frontier model how many days of the week contain the letter d, and watch it try. Sometimes it answers four. Sometimes six. The answer is seven, because every day of the week ends in "day", which a five-year-old can see in a single glance. The same model, on a different turn, might find a 27-year-old vulnerability in OpenBSD, an operating system whose entire reputation is built on three decades of paranoid code review, and which no human researcher in those three decades had managed to notice was broken. That is what jagged means. The intelligence is real, and the surface of it bears almost no resemblance to the contours of human ability. Most of the conversation since the term was coined has stayed at the level of the model, comparing GPT against Claude or Gemini against Grok and mapping the terrain by benchmark, as if the question were which model is generally smarter rather than where each model's spikes happen to point. Building an attack harness has changed how I see that map, because the jaggedness lives at more than one level, and the level it lives at most powerfully is the one that almost nobody is talking about. The picture I keep coming back to is a wheel with spokes. Each spoke is a direction in capability-space where some combination of people, capital, and data has been invested. Some spokes grew from the model side, by accident or on purpose. Some spokes grew from the harness side, where a team took a generalist model and built the exact scaffolding their domain needed. The durable products of this era will mostly be the combination of both, a model with a natural lean toward the relevant axis paired with a harness that knows how to climb it. Coding is a spike. Legal is a spike. Protein structure is a spike. Clinical reasoning is a spike. Offensive security is a spike. Each of them gets taller every quarter. The reality is though, you do not need to be a frontier lab to sit on the tip of one of these spokes. You need a model with the right natural lean, which is now a commodity available by API, and a harness built by people who know the target domain cold. That is a small team of the right engineers with conviction and a clear thesis about where the spike points. A group of five people, regardless of their moral standing, can climb to the pointiest end of one of these spokes faster than the institutions built to defend against them can react. AI is the great equaliser, and it equalises specifically at the harness layer. The model is the public good, accessible to everyone for roughly the same price. So in my opinion, the harness is where the asymmetry lives, and the harness costs almost nothing to build relative to what it can do once built. Cybersecurity is the cleanest case study for this asymmetry, because the field has more than twenty years of public history showing how the contest between attack and defence plays out under normal conditions. On the defensive side, the industry spent those two decades building infrastructure: endpoint detection and response systems that watch every process on every machine, security information and event management platforms that aggregate logs from across an enterprise, the slow shift toward zero-trust architectures that assume any given network connection is hostile by default, threat intelligence sharing arrangements between companies and governments, mandatory breach disclosure laws, bug bounty programmes that pay researchers to find flaws before criminals do, and the long professionalisation of the security workforce itself. On the offensive side, attackers spent the same two decades under continuous evolutionary pressure, finding new techniques when their old ones got patched and falling back on the old ones whenever defenders failed to learn the lessons of the previous decade, which they routinely did. The equilibrium that emerged was an uneasy one. submitted by /u/theonejvo [link] [comments]
- AI starting to look economically impossible outside hyperscalers?by /u/houmanasefiau (Artificial Intelligence) on May 17, 2026 at 10:21 am
Am I crazy or is AI starting to look economically impossible outside hyperscalers? The deeper I look into capex, power infrastructure, cooling, debt markets, and GPU costs… …the more it feels like only Google, Microsoft, Amazon, and Meta can realistically afford this game long term. submitted by /u/houmanasefiau [link] [comments]
- AI benchmarks matter less than whether models can handle boring real-world responsibilityby /u/thirdaccountttt (Artificial Intelligence) on May 17, 2026 at 9:52 am
I think AI discussion is still way too obsessed with benchmark scores, model rankings and flashy demos Those things matter, but they are not what will decide whether AI is actually trusted in normal life The real test is boring responsibility Can the model follow instructions without quietly ignoring the awkward parts? Can it admit uncertainty instead of sounding confident? Can it handle edge cases? Can it remember constraints across a long task? Can it stop when it should escalate to a human? Can it produce work that is auditable instead of just impressive-looking? A model can score well on exams and still be dangerous in real use if it invents details, misses exceptions, over-complies, or gives polished answers that hide weak reasoning This matters more for actual deployment than whether one model is slightly better at coding puzzles or abstract reasoning tests For healthcare, education, legal admin, finance, customer support, welfare systems, moderation, HR and public services, the key question is not “how smart is it?” It is “can you safely give it responsibility?” I think we are overvaluing intelligence and undervaluing reliability, restraint, traceability and escalation Curious where people disagree: are benchmarks still the best proxy we have, or are they distracting us from the qualities that actually matter in deployment? submitted by /u/thirdaccountttt [link] [comments]

























96DRHDRA9J7GTN6